Dynavax: MVC Begins Phase 1 Trial For Adjuvanted Vaccine Candidate To Prevent COVID-19

(RTTNews) - Medigen Vaccine Biologics Corp. and Dynavax Technologies Corp. (DVAX) announced that MVC has obtained a Taiwan government subsidy for successfully initiating a phase 1 clinical trial in Taiwan. The grant was earmarked by the government for purposes of research and development of a locally produced COVID-19 vaccine. The subsidy will be released at agreed upon milestones in the total amount of up to $16.4 million.

The first participant in phase 1 clinical trial was dosed with MVC's COVID-19 vaccine combined with Dynavax's CpG 1018 adjuvant in early October.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos


    Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

    Learn More